STAT+: Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments

Clinical trial results reported by Amgen may be enough to confirm the U.S. approval of its KRAS-targeting lung cancer drug called Lumakras — but come with disappointments as well.

Click to view original post